Investigation Report on China Celecoxib Market, 2010-2019
|出版商||China Research and Intelligence||商品編碼||332765|
|出版日期||內容資訊||英文 20 Pages
|Celecoxib的中國市場 Investigation Report on China Celecoxib Market, 2010-2019|
|出版日期: 2015年06月11日||內容資訊: 英文 20 Pages||
由GD Searle及Pfizer所開發的Celecoxib，在1999年以Celebrex這個商品名在市場上推出，自那之後便成了公譽抗風濕藥的No. 1品牌。Pfizer的製造商Celebrex在2009年9月通過CFDA(中國國家食品藥品監督管理局)核可上市後，在中國市場銷售量急速上升。2005年2000萬人民幣的銷售量到2014年已增加到1億6400萬人民幣的規模。
Currently, there are over 30 million people around the world using non-steroidal anti-inflammatory drugs (NSAIDs) as anti-inflammatory pain-relief drugs. However, many drugs under the category of NSAIDs cause gastrointestinal adverse reactions such as ulcer, perforation and bleeding. The latest research has shown that among all the NSAIDs, celecoxib reports the lowest number of cases of gastrointestinal side effects. As a kind of NASIDs, celecoxib is mainly used for osteoarthritis, rheumatoid arthritis and the adjuvant treatment of familial adenomatous polyposis. It is reported that over 100 million people in China suffer from arthritis, among which about 10% use celecoxib.
Developed by GD Searle & Pfizer, celecoxib came into the market in 1999 under the trade name of Celebrex. Ever since its debut in the US in Feb. 1999, celecoxib has been widely used and set a record for the largest amount of prescriptions among all the new drugs in that year. Celecoxib has become the No. 1 brand of anti-rheumatic drug with a reputation as the most successful branded drug in the market.
In Sep. 2000, celebrex (celecoxib capsule) made by Pfizer Inc was approved by CFDA to enter China. Celecoxib develops fast then, annual sales rising from CNY 20 million in 2005 to CNY 164 million in 2014 and CAGR reaching up to 24.59% during the period of 2005-2014. Celecoxib enjoys a vast demand in China. Currently, celecoxib in the Chinese market mainly come from two companies: Pfizer Inc and Shire Plc. They monopolize the Chinese market and Pfizer has a larger market share of over 98%, sales value reaching up to CNY 162 million in 2014.
The market size of celecoxib is expected to keep expanding in China in the next few years.
Readers can get at least the following information from this report:
The author suggests the following groups of people purchase this report: